• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    LAVA Therapeutics to Move Extraordinary General Meeting to Early November 2025

    9/30/25 7:00:00 AM ET
    $LVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $LVTX alert in real time by email

    Additional time enables LAVA Therapeutics to address potential liabilities and confirm net cash to be delivered to Shareholders. LAVA Therapeutics and XOMA Royalty anticipate closing the announced acquisition in the fourth quarter of 2025.

    UTRECHT, The Netherlands and PHILADELPHIA, Sept. 30, 2025 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (the "Company" or "LAVA") (NASDAQ:LVTX) today announced that the Company has decided to cancel the Extraordinary General Meeting of Shareholders (the "EGM") scheduled to occur on September 30, 2025 to consider and approve certain matters related to the Company's previously announced transaction with XOMA Royalty Corporation ("XOMA"), pursuant to which XOMA made an offer to purchase all of the issued and outstanding common shares in the capital of the Company (the "Transaction").

    The Company is canceling the EGM to continue discussions with XOMA concerning the terms of the Transaction, including the Company's estimated cash forecast and the consideration payable to the Company's shareholders in the Transaction. Both the Company and XOMA Royalty remain committed to completing the Transaction.

    "We are committed to closing this transaction and look forward to working collaboratively with the LAVA team to further define LAVA's cash forecast in an effort to close this transaction in an expeditious manner," stated Owen Hughes, CEO of XOMA Royalty.

    The EGM is expected to be reconvened by early November 2025. The meeting date, record date and location for the reconvened EGM will be determined and announced by the Company at a later date. Votes already cast by shareholders in respect of the EGM will not count towards the voting outcome on the matters proposed to the reconvened EGM. Shareholders as of the record date for the reconvened EGM will have to cast their votes (or cast their votes again, as the case may be) for their votes to count towards the voting outcome.

    About LAVA Therapeutics

    LAVA Therapeutics N.V. is a biopharmaceutical company that has developed several clinical-stage bispecific gamma delta T cell engagers using its proprietary Gammabody® platform, including JNJ-89853413, targeting CD33 and hematologic cancers (NCT06618001), partnered with Johnson & Johnson, and PF-08046052, targeting EGFR and solid tumors (NCT05983133), partnered with Pfizer, Inc. For more information on LAVA, please visit www.lavatherapeutics.com.

    Gammabody® is a registered trademark of LAVA Therapeutics N.V.

    Cautionary Note on Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "anticipate", "believe", "could", "will", "may", "expect", "should", "plan", "intend", "estimate", "potential", "suggests", and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on the Company's expectations and assumptions as of the date of this press release and are subject to various risks and uncertainties that may cause actual results to differ materially from these forward-looking statements. As a result, a number of important factors could cause actual results to differ materially from those indicated by such forward-looking statements, including: the risk that the Transaction may not be completed in a timely manner, or at all, which may adversely affect the Company's business and the price of its common shares; the risk that the terms of the Transaction may be revised to be less favorable to the Company's shareholders; the delay or failure of the terms of the Transaction to be revised or of the offer conditions to be satisfied (or waived), including insufficient common shares of the Company being tendered in the offer, any of which delays may impact the amount payable to the Company's shareholders in the Transaction; the possibility that competing offers will be made; significant costs associated with the Transaction; the risk that any shareholder or other litigation in connection with the Transaction may result in significant costs of defense, indemnification and liability; the risk that activities related to the CVR agreement may not result in any value to the Company's shareholders; the possibility that prior to the completion of the Transaction, the Company's or XOMA's business may experience significant disruptions due to transaction-related uncertainty; the effects of disruption from the transactions of the Company's business and the fact that the announcement and pendency of the Transaction may make it more difficult to establish or maintain relationships with employees, manufacturers, suppliers, vendors or business partners; the occurrence of any event, change or other circumstance that could give rise to the termination of the purchase agreement; as well as potential adverse effects on the Company's business condition and results from general economic and market conditions and overall fluctuations in the United States and international equity markets, including as a result of inflation, heightened interest rates, recent and potential future pandemics and other health crises, and hostilities, including the Russian invasion of Ukraine and the conflict in the Middle East. These and other risks are described in greater detail under the caption "Risk Factors" in the Company's most recent Annual Report on Form 10-K and other filings the Company makes with the U.S. Securities and Exchange Commission (the "SEC"). The Company assumes no obligation to update any forward-looking statements contained herein whether as a result of any new information, future events, change in expectations or otherwise, except as otherwise required by law.

    Additional Information and Where to Find It

    The description contained in this press release is for informational purposes only and is not a recommendation, an offer to buy or the solicitation of an offer to sell any shares of the Company's common shares. XOMA filed a Tender Offer Statement on Schedule TO with the SEC and the Company filed a Solicitation/Recommendation Statement on Schedule 14D-9 with the SEC related to the tender offer. The Company also filed a proxy statement in connection with the originally scheduled EGM at which the Company shareholders were requested to vote on certain proposed resolutions (the "EGM Proposals") in connection with the Transactions. The Company plans to send a revised proxy statement and proxy card to each shareholder entitled to vote at the reconvened extraordinary general meeting. INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE REVISED PROXY STATEMENT REGARDNG THE EXTRAORDINARY GENERAL MEETING AND THE TENDER OFFER MATERIALS (INCLUDING THE OFFER TO PURCHASE, A LETTER OF TRANSMITTAL AND RELATED DOCUMENTS) AND THE SOLICITATION/RECOMMENDATION STATEMENT ON SCHEDULE 14D-9 REGARDING THE OFFER, AS THEY MAY BE AMENDED OR SUPPLEMENTED FROM TIME TO TIME, BECAUSE THEY CONTAIN IMPORTANT INFORMATION THAT INVESTORS AND SECURITY HOLDERS SHOULD CONSIDER BEFORE MAKING ANY DECISION REGARDING TENDERING THEIR SHARES (INCLUDING THE TERMS AND CONDITIONS OF THE OFFER) OR MAKING ANY VOTING DECISION FOR THE EXTRAORDINARY GENERAL MEETING. Investors and security holders may obtain a free copy of these statements and other documents filed with the SEC at the website maintained by the SEC at www.sec.gov or by directing such requests to the information agent for the Offer, which will be named in the tender offer statement. Investors and security holders may also obtain, at no charge, the documents filed or furnished to the SEC by LAVA under the "SEC Filings" subsection of the "Financials & Filings" section of the Company's website at https://ir.lavatherapeutics.com or by accessing the Investor Relations sections of XOMA's website at https://www.investors.xoma.com.

    Participants in the Solicitation

    The Company, its directors and executive officers, and other members of its management and employees, as well as XOMA and its directors and executive officers, may be deemed to be participants in the solicitation of proxies from the Company's shareholders in connection with the EGM Proposals. Information about the Company's directors and executive officers and their ownership of Shares is set forth in the proxy statement for the Company's 2025 annual general meeting of shareholders, which was filed with the SEC on April 28, 2025. Information about XOMA's directors and executive officers is set forth in the proxy statement for XOMA's 2025 annual meeting of shareholders, which was filed with the SEC on April 15, 2025. Shareholders may obtain additional information regarding the direct and indirect interests of the participants in the solicitation of proxies in connection with the EGM Proposals, including the interests of the Company's directors and executive officers in the Transaction, which may be different than those of the Company's shareholders generally, by reading the proxy statement and other relevant documents regarding the Transaction which will be filed with the SEC.

    LAVA Therapeutics Investor Contact

    Fred Powell

    LAVA Therapeutics

    +1 800-311-6892

    [email protected]



    Primary Logo

    Get the next $LVTX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $LVTX

    DatePrice TargetRatingAnalyst
    12/12/2024$11.00 → $2.00Outperform → Market Perform
    Leerink Partners
    12/11/2024Mkt Outperform → Mkt Perform
    JMP Securities
    10/25/2022$9.00Buy
    H.C. Wainwright
    11/16/2021$24.00 → $20.00Outperform
    SVB Leerink
    8/17/2021$26.00 → $24.00Outperform
    SVB Leerink
    More analyst ratings

    $LVTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Versant Venture Capital Vi, L.P. sold $4,068,829 worth of shares (2,903,403 units at $1.40) (SEC Form 4)

    4 - LAVA Therapeutics NV (0001840748) (Issuer)

    9/23/25 4:33:39 PM ET
    $LVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Versant Venture Capital Vi, L.P. sold $2,502,261 worth of shares (1,684,434 units at $1.49) (SEC Form 4)

    4 - LAVA Therapeutics NV (0001840748) (Issuer)

    9/18/25 6:49:18 PM ET
    $LVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    New insider Cooperatieve Gilde Healthcare Iv U.A. claimed ownership of 5,421,170 shares (SEC Form 3)

    3 - LAVA Therapeutics NV (0001840748) (Issuer)

    4/8/25 6:19:03 PM ET
    $LVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LVTX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    LAVA Therapeutics to Move Extraordinary General Meeting to Early November 2025

    Additional time enables LAVA Therapeutics to address potential liabilities and confirm net cash to be delivered to Shareholders. LAVA Therapeutics and XOMA Royalty anticipate closing the announced acquisition in the fourth quarter of 2025. UTRECHT, The Netherlands and PHILADELPHIA, Sept. 30, 2025 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (the "Company" or "LAVA") (NASDAQ:LVTX) today announced that the Company has decided to cancel the Extraordinary General Meeting of Shareholders (the "EGM") scheduled to occur on September 30, 2025 to consider and approve certain matters related to the Company's previously announced transaction with XOMA Royalty Corporation ("XOMA"), pursuant to which XO

    9/30/25 7:00:00 AM ET
    $LVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    LAVA Reports Second Quarter 2025 Financial Results and Provides Corporate Update

    Announced entry into an agreement to be acquired by XOMA Royalty Corporation for between $1.16 and $1.24 per share in cash, plus a contingent value right related to LAVA's two partnered assets and unpartnered programsConsummation of acquisition expected to occur in the fourth quarter of 2025, subject to customary closing conditions and an extraordinary general meeting of shareholdersAnnounced decision to discontinue development of LAVA-1266 for acute myeloid leukemia and myelodysplastic syndrome; wind-down of the program has been initiated UTRECHT, The Netherlands, and PHILADELPHIA, Aug. 13, 2025 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ:LVTX, "LAVA, " or the "Company")), a clin

    8/13/25 4:55:00 PM ET
    $LVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    XOMA Royalty Enters into Agreement to Acquire LAVA Therapeutics for Between $1.16 and $1.24 Per Share in Cash, Plus a Contingent Value Right

    EMERYVILLE, Calif. and UTRECHT, The Netherlands and PHILADELPHIA, Aug. 04, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation ("XOMA Royalty") (NASDAQ:XOMA) and LAVA Therapeutics N.V. ("LAVA") (NASDAQ:LVTX) announced today they have entered a definitive share purchase agreement (the "Purchase Agreement" and the transactions set forth in the Purchase Agreement, the "Transactions") whereby XOMA Royalty will acquire LAVA for (i) between $1.16 and $1.24 per share in cash, consisting of (A) USD $1.16 (the "Base Price Per Share") in cash per share (the "LAVA common stock"), plus (B) an additional amount of cash of up to $0.08 per Share (such amount as finally determined in accordance with the Pur

    8/4/25 7:30:00 AM ET
    $LVTX
    $XOMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LVTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    LAVA Therapeutics downgraded by Leerink Partners with a new price target

    Leerink Partners downgraded LAVA Therapeutics from Outperform to Market Perform and set a new price target of $2.00 from $11.00 previously

    12/12/24 8:11:38 AM ET
    $LVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    LAVA Therapeutics downgraded by JMP Securities

    JMP Securities downgraded LAVA Therapeutics from Mkt Outperform to Mkt Perform

    12/11/24 7:55:00 AM ET
    $LVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright initiated coverage on LAVA Therapeutics with a new price target

    H.C. Wainwright initiated coverage of LAVA Therapeutics with a rating of Buy and set a new price target of $9.00

    10/25/22 6:28:17 AM ET
    $LVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LVTX
    SEC Filings

    View All

    SEC Form DEFA14A filed by LAVA Therapeutics N.V.

    DEFA14A - LAVA Therapeutics NV (0001840748) (Filer)

    9/30/25 7:33:24 AM ET
    $LVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    LAVA Therapeutics N.V. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - LAVA Therapeutics NV (0001840748) (Filer)

    9/30/25 7:30:44 AM ET
    $LVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13G filed by LAVA Therapeutics N.V.

    SCHEDULE 13G - LAVA Therapeutics NV (0001840748) (Subject)

    9/26/25 4:01:22 PM ET
    $LVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LVTX
    Leadership Updates

    Live Leadership Updates

    View All

    LAVA Therapeutics Announces Appointment of Christy J. Oliger to its Board of Directors

    UTRECHT, The Netherlands and PHILADELPHIA, March 09, 2023 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ:LVTX), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma-delta T cell engagers, today announced the appointment of Christy J. Oliger to its board of directors effective March 9, 2023. Ms. Oliger brings extensive commercial, portfolio management, and senior leadership experience to the role. Additionally, Stefan Luzi, Ph.D., will step down from his role on the LAVA Board. "As an accomplished leader in the pharmaceutical and biotechnology industry with deep experience in oncology, Ms. Oliger brings over three deca

    3/9/23 8:05:00 AM ET
    $LVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    LAVA Therapeutics Announces the Appointment of Dr. Charles Morris as Chief Medical Officer

    UTRECT, The Netherlands and PHILADELPHIA, Feb. 06, 2023 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq LVTX), an immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma-delta T cell engagers to transform the treatment of cancer, today announced that Dr. Charles Morris has joined LAVA as chief medical officer effective February 6, 2023. Dr. Morris will replace Benjamin Winograd, MD, PhD. "During a 25-year tenure in the industry, Dr. Morris has demonstrated a proven track record of advancing novel oncology product candidates from clinical development through global regulatory approvals," said Stephen Hurly, president and chief executive offi

    2/6/23 7:00:00 AM ET
    $LVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    LAVA Therapeutics Provides Business Update and Reports Third Quarter Financial Results

    LAVA-051 updated interim data from ongoing Phase 1/2a clinical trial in patients with relapsed or refractory chronic lymphocytic leukemia and multiple myeloma to be presented at 2022 American Society of Hematology (ASH) Annual MeetingPresented LAVA-051 clinical pharmacodynamic data demonstrating consistency with mechanism of action data at the Society for Immunotherapy for Cancer (SITC) 2022 Annual MeetingAnnounced exclusive worldwide license agreement with Seagen to advance LAVA-1223, a preclinical bispecific gamma delta T cell engager for EGFR-expressing solid tumorsCash and investments of $92.7 million as of September 30, 2022, plus$50.0 million received from Seagen in October provide cas

    11/16/22 4:05:00 PM ET
    $LVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LVTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D/A filed by LAVA Therapeutics N.V. (Amendment)

    SC 13D/A - LAVA Therapeutics NV (0001840748) (Subject)

    3/7/24 7:09:56 PM ET
    $LVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by LAVA Therapeutics N.V. (Amendment)

    SC 13G/A - LAVA Therapeutics NV (0001840748) (Subject)

    2/14/24 4:26:22 PM ET
    $LVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by LAVA Therapeutics N.V. (Amendment)

    SC 13D/A - LAVA Therapeutics NV (0001840748) (Subject)

    11/9/23 4:37:57 PM ET
    $LVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LVTX
    Financials

    Live finance-specific insights

    View All

    XOMA Royalty Enters into Agreement to Acquire LAVA Therapeutics for Between $1.16 and $1.24 Per Share in Cash, Plus a Contingent Value Right

    EMERYVILLE, Calif. and UTRECHT, The Netherlands and PHILADELPHIA, Aug. 04, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation ("XOMA Royalty") (NASDAQ:XOMA) and LAVA Therapeutics N.V. ("LAVA") (NASDAQ:LVTX) announced today they have entered a definitive share purchase agreement (the "Purchase Agreement" and the transactions set forth in the Purchase Agreement, the "Transactions") whereby XOMA Royalty will acquire LAVA for (i) between $1.16 and $1.24 per share in cash, consisting of (A) USD $1.16 (the "Base Price Per Share") in cash per share (the "LAVA common stock"), plus (B) an additional amount of cash of up to $0.08 per Share (such amount as finally determined in accordance with the Pur

    8/4/25 7:30:00 AM ET
    $LVTX
    $XOMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    LAVA Therapeutics to Present Initial Phase 1/2a Clinical Trial Dose Escalation Data of LAVA-051 in Chronic Lymphocytic Leukemia and Multiple Myeloma Patients at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

    UTRECHT, The Netherlands and PHILADELPHIA, June 01, 2022 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ:LVTX), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma delta T cell engagers to transform the treatment of cancer, today announced the presentation of initial dose-escalation data from the Phase 1/2a clinical trial of LAVA-051 in patients with chronic lymphocytic leukemia (CLL) and multiple myeloma (MM) at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago and virtually June 3-7, 2022. "These dose-escalation data from the first four cohorts of our Phase 1/2a clinical tria

    6/1/22 7:00:00 AM ET
    $LVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care